Podcasts about Mariposa

En el Día Mundial de las Enfermedades Raras recogemos el testimonio de dos aragoneses que conviven con patologías poco frecuentes: la epidermólisis bullosa y la miastenia gravis. María Juárez, portavoz de la Asociación DEBRA Piel de Mariposa, nos acerca la realidad de quienes viven con piel de mariposa y las necesidades de las familias. Por su parte, José Antonio Bernad, marido de una persona con miastenia gravis, comparte cómo es el día a día con esta enfermedad y la importancia del apoyo social y sanitario.

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Luis Herrero entrevista a Lidia Osorio, madre de Leo.

“ElectroRecicla” recolecta toneladas de residuos electrónicos CDMX activa Alerta Amarilla por frío en Milpa Alta y TlalpanMariposa monarca en peligroMás información en nuestro Podcast

Mateo plants seeds in his grandmother's tiny corner of the garden and discovers that his laughter can make things grow, even after a mistake that makes his heart heavy. This is a story about a boy learning to bring joy back to himself and to the plants he loves.Want the full transcript, English translation, and vocabulary list?Become a member of our Patreon community and turn every episode into a full Spanish learning experience.Have a story you'd love to hear on the podcast? We'd love to read it! Email us at hello@spanishstoriesforkids.com=============Mateo planta semillas en el pequeño rincón del jardín de su abuela y descubre que su risa puede hacer que las cosas crezcan, incluso después de un error que le pesa en el corazón. Es la historia de un niño que aprende a devolver la alegría a sí mismo y a las plantas que cuida.¿Quieres la transcripción completa, la traducción al inglés y la lista de vocabulario? Hazte miembro de nuestra comunidad en Patreon y transforma cada episodio en una experiencia completa para aprender español.¿Tienes una historia que te gustaría que leamos? ¡Nos encantará compartirla! Escríbenos a hello@spanishstoriesforkids.com

 In tiny community of Mariposa, an excursion on the Mariposa Belle steamboat is the hottest ticket in town. What could go wrong? Stephen Leacock, today on The Classic Tales Podcast.   Welcome to this VINTAGE episode of The Classic Tales Podcast. Thank you for listening.     Let's talk about ads. Now, most podcasts offer a subscription where you can pay $10 or so a month, and you get to listen to their show with no ads, and get a few bonus episodes. Here's the thing – this largely goes to benefit the podcast platforms. The actual creators don't get much.   So, I created a better plan. For $9.99 per month, you get unlimited downloadable and streamable access to the entire Classic Tales Library. I've been building this for 18 years. This gives you access to longer books that wouldn't work in the podcast format. Books like Nicholas Nickleby, Moby Dick, or The Hunchback of Notre Dame. Only about a quarter of the books in the library were released through the podcast. So you can instantly download and listen to whatever you want, all the time. This is the Audiobook Library Card.    Go to audiobooklibrarycard.com or follow the link in the show notes, and download and listen all you want.   Go to audiobooklibrarycard.com or follow the link in the show notes.     And now, The Marine Excursion of the Knights of Pythias, by Stephen Leacock      Follow this link to get The Audiobook Library Card for $9.99/month       Follow this link to subscribe to our YouTube Channel:       Follow this link to subscribe to the Arsène Lupin Podcast:     Follow this link to follow us on Instagram:     Follow this link to follow us on Facebook:

LA Public Press reporter Phoenix Tso joins us for our first podcast of the year. Tso covered mutual aid efforts immediately after last January's Eaton Fire in the Altadena area of the San Gabriel Mountains. Marking the anniversary of the 14,000 acre fire that destroyed 10,000 structures and took at least 19 lives, Tso checked in again with small business owners rebuilding their lives back from the disaster. Struggles are plenty: insurance claims, fire remediation, lost income, lost neighbors and customers, and real estate development. The stories Tso shares with us are somber, but remind us why the community needs support from the San Gabriel Valley at large. A lightly edited transcript of the conversation can be found below. Streetsblog's San Gabriel Valley coverage is supported by Foothill Transit, offering car-free travel throughout the San Gabriel Valley with connections to the A Line Stations across the Foothills and Commuter Express lines traveling into the heart of downtown L.A. To plan your trip, visit Foothill Transit. "Foothill Transit. Going Good Places."Sign-up for our SGV Connect Newsletter, coming to your inbox on Fridays! Chris Greenspon - This is SGV Connect 145. I'm Chris Greenspon. This is our first podcast of the new year. We hope you all had a good break. Quickly, before we begin, though, I just want to remind you that Streetsblog's San Gabriel Valley coverage is supported by Foothill Transit, offering car free travel throughout the San Gabriel Valley with connections to the A Line Stations across the foothills and commuter express lines traveling into the heart of downtown LA. To plan your trip, visit Foothill transit.org. Foothill Transit "Going good places".  Today, we're looking back at the one year anniversary of the Eaton Fire and recovery efforts to keep the community intact. Here as our guest, we have Phoenix Tso reporter for LA Public Press. Phoenix, welcome back to SGV Connect.  Phoenix Tso - Thank you for having me.  Chris - So earlier this week, you filed a story checking in with business owners in Altadena who've been able to reopen a year after the fire. How are people holding up now, a year later?  Phoenix - Yeah, I just did a story on small business owners whose businesses were affected by the Eaton Fire in Altadena one year later. I think it's kind of a mixed bag. I talked to a bunch of people who were able to reopen. Some, like, just a couple months ago, reopened. One person actually, technically never closed. She said she was the only person in her shopping plaza, without a working air conditioning and a patchy roof,  all burned up.  But the building was luckily intact, and her store was luckily intact. She runs a print and copying shop. So, yeah, it's a mixed bag.  Some people, their businesses burned down completely. It's a total loss. One person I talked to runs a martial arts studio, and she actually bought the land that her studio was standing on. She's trying to rebuild, trying to raise the money, and she says that, like, it'll probably take three to five years for her to come back and for the community to really come back. Yes, there's businesses that have reopened, but there's just not as many people back in Altadena one year later.  Chris - And what's the mood? Phoenix - It's somber. I would say.  I think there's still a big community feel, though. A lot of these businesses were pillars of the community, and they're where people gather still…or gather even more. For example, Fair Oaks Burger, they closed during the fire, and they didn't reopen until June, basically because of smoke remediation issues and debris and everything like that. But they kept doing mutual aid operations in their parking lot. They worked with the World Central Kitchen to distribute food, and they ended up partnering with different groups to do grocery distributions. So they've still been around in Altadena, and there are a lot of community events there, and a lot of the community really gathers there. Business is slower than before, but people did come back after Fair Oaks Burger reopened.  Chris - What kind of community is this and why do people want to preserve it? Obviously, every time a community has a tragedy, we hear some of the same descriptors. But what makes Altadena Altadena? Phoenix - I think Altadena is special because it's technically urban. It's close to LA but it really does have a small town feel. I wonder if Altadena residents would agree with me…of like a Gilmore Girls type of feel. It's right by the mountains. It's beautiful up there. It's a little isolated and out of the way.  People who like a quiet, sort of nature…very close to nature, type of community that still is also close to urban amenities. I think they love that. As has been said it's a historically black community. It's one of the few communities where black people are allowed to own homes for a long time, and that community has been affected heavily by the fire.There's a big question whether they'll be able to make a comeback, especially with a lot of corporate developers buying up lots that have burned down.  So it's actually a very diverse working class community as well. It's kind of unique in that sense, very different from the Palisades fire. Where the Pacific Palisades is one of the wealthiest communities in LA County. The diversity, the mix, but also like a very tight knit community. I think when you go out to community events, there is a small business fair on Small Business Saturday, right after Thanksgiving, you could definitely see a lot of the community out there, and people knowing each other, and really breaking bread together. Chris - And it still has a little bit of that 'Dena' cultural feel with the hippie stuff and the art galleries.  Phoenix - Yeah, definitely. And in fact, I talked to an art gallery owner who started dedicating his gallery to artists affected by the fire in Altadena and Pasadena. And he said, "Yeah, the support that people are showing those artists is really amazing." Chris - So you spoke to a range of different types of businesses. You spoke to the gallerist. You spoke to somebody who's trying to get a martial arts studio back up and running, hopefully in a few years. You spoke to somebody who owned a print and copy shop and I think a restaurant or two. Overall, what are the challenges that they spoke about in getting reopened?  Phoenix - Yeah, I think their insurance companies were a big challenge.  I interviewed a lot of business owners at Mariposa junction, which is one of the few shopping areas where one of the buildings burned down, but one did not burn down. So those businesses have come back. So I think that's a big challenge.  Oh, the gallery owner I talked to. His name is Ben McGinty. He said that the biggest challenge for him is being back when everybody else has lost everything and it's a very like sobering thought, for sure.  But also, people said that the challenge was getting their shops remediated in a timely manner, they had to wait months for that to happen. I think some of them did it themselves and still need to get reimbursed by their insurance company. I guess some insurance companies were understanding. Some, just gave an attitude, like, "why are you asking?" It's like, "oh, I'm a policyholder. Like, why wouldn't I ask for this, for, you know, this to be paid out?"  Yeah, I think having the money to be able to reopen and rebuild, having a good landlord who would like not charge rent while you're not in the store and an insurance company to help with repairs. Those are all challenges.  Chris - So how are folks surviving, or is it? Are they getting grants? Are they getting help from the city? Are they getting community buyouts? What's going on?  Phoenix - Yes, there are a lot of grants. Fair Oaks Burger, it's kind of interesting. You know, Rick Caruso, the billionaire businessman, his foundation has issued a good amount of grants. Interesting to see his name in the mix there.  There are a lot of grants from corporations, different chambers of commerce. There are low interest loans, or no interest loans that people have been able to get another challenge is the red tape it takes to reopen in LA County. The owner of Fair Oaks Burger talked about that a lot, and she said that, if they make the process easier with a little less red tape. She thinks  more businesses will be able to come back more easily.  Chris - So where are we seeing real estate movement? You alluded to this a little bit.  Phoenix - Oh, yeah, I haven't looked at this in a lot of detail, but I've seen a lot of reports.A lot of the lots, I think it's several hundred residential lots that have a lot of people have  put their lots up for sale because they aren't able to rebuild.  That's a similar challenge. The insurance companies have not come through for people who lost their homes, which is really horrible to hear. So they're selling their lots. And a lot of corporate developers, LLCs, are buying up those lots. It remains to be seen what they're doing with them.  I saw a report where  one of them is being constructed right now, and it's kind of interesting. The home they're building is for sale for at least a million dollars, or something like that. I don't know how a lot of people can afford that. So, there are a lot of community groups who are really tracking that and are really trying to advocate for community land trusts and for community minded people to buy up these lots and to be able to sell or rent them to working class folks, just to preserve the diversity of Altadena, to let allow people to be able to come back.  I read last year, groups had asked for, maybe $500 million from the state, which they didn't get. I wouldn't be surprised if they're trying again. But so far, I think there hasn't been a lot of support from, you know, from the state to actually do something to preserve Altadena as it was and has been. Chris - Yeah, it sounds like an uphill struggle. So what should we keep an eye out for as we're wrapping up this interview going forward with LA Public Press, with Altadena and your reporting? Phoenix - Oh, I'll keep covering Altadena. I'm covering calls for a state investigation into the evacuation response by LA County. I will be looking into who's buying these residential lots and what they're doing with them as a whole. We are still covering everything LA County, especially the immigration raids, police accountability, housing, organizing, you name it. Chris - So thanks for joining us once again on SGV Connect.  Phoenix - Thanks for having me again.  Chris - That's Phoenix Tso reporter for LA Public Press covering all things Eaton, fire, mutual aid, Chinatown and more. Check out hers and all the other fine work from LA Public Press, and if you can donate, they do good work. And if you have anything left over, donate to Streetsblog. I'm Chris Greenspon. Thanks for listening.   

La salud de #YolandaAndrade ha mantenido a todos en vilo, pero su hermana Marilé trae noticias frescas. Sin embargo, lo que más impactó a todos no fue solo lo que dijo, ¡sino lo que pasó en plena entrevista! Una mariposa la sorprendió, dejando a muchos pensando en señales y buena energía.

Si, como si fuera crear un remanso de paz en nuestras vidas y dejarnos llevar por la lectura. Eso propone Miguel Ángel Cayuela en sus retiros lectores Un Remanso, y eso hacemos en el programa. Repasamos a sus próximas autoras invitadas, Manuela Carmena que propone una guía de lectura sobre autores africanos y Lana Orujo y su gran novela "Han Cantado Bingo" que Miguel Ángel define como la novela de este 2025. Los retiros se realizan en diferentes puntos de la Península y también en autocaravanas para leer, como lo han hecho en este 2025 a Virgina Woolf y su gran obra "La señora Dalloway" Escuchamos un framento de esa obra en voz de Marta Orquín, y también a Montse Soto interpretando un párrafo de "Han Cantado Bingo" o a Consol Saénz mandándonos un mensaje para encontrar tiempo para leer. Y nos acompaña la música de: TITI ZARÓ- Gawé; FRANÇOISE ATLAN- Hublot bleu; TAMIKREST- Aicha; NAWAL- Hima; FLOWPIANO- Alas de MARIPOSA; AZIZA BRAHIM- Marhabna; ORHAM OLMEZ- Damla Damla; BADIAA BOUHRIZI- Mana’a; MARIA RODES+ MARTI SALES+ REFREE- La visita. Escuchar audio

Despedimos el año con dos programas donde mezclamos el magazine habitual de todos los meses dedicados al metal nacional, y tertulias que tanto os gustan con esta vez, un invitado especial. Se acerca Chechu Nos para acompañar a Sabino y Kikemaiden en dos programas especiales dedicados al metal nacional pero sobre todo, para debatir y poner sobre la mesa temas de nuestra escena y de todo lo que nos afecta en el metal, y por qué no decirlo, en la vida misma. Una gran primera parte donde nos acompañaran algunos amigos del REA metal magazine. Otro lujazo de programa. -ANKOR: MADARA -AGAINS THE WAVES: THE SOUND. -PROYECTO MORDRAKER: NEGRURA. ------------------- -ZONA CORE (BEA BATHORY)/WE EXIST EVEN DEAD: SHATTER AND FALL. -FEEDBACK EXTREMADURA ROCK (PEDRO BARROSO)/ JAVIER LUQUE: GOOD VIBES. -METALINGUS (AIDA GUILLEM)/ AGAINST MYSELF & SAUROM: ACT II REFLECTIONS. ------------------- -IAN WILDE: GUIDE US HOME. -LEATHER BOYS: HAIRCUT & ATTITUDE. -BLACK BOMBER: ROCK & ROLL TODAY, HANGOVER TOMORROW. -UNREAL OVERFLOWS: TEARINGTHE LAYERS OF REALITY. -------------------- -NOCHE DE ROCK (JOAKI SEZ NAUS)/ GREY GIANT: OSTRICH HEAD. -ZONA NORTE (CARLOS CITOLER)/ AU D´ASTI!: CONTRA EL VIENTO. -PLANETA RUIDO (KIKO)/LATZEN: MEMENTO MORI -------------------- -WARG: AS THE WORLDS FALL DOWN.

In this episode of Busy Gallivanting, I'm joined by Kate as we explore Yosemite National Park — one of the most iconic, photographed, and awe-inspiring destinations in the U.S. We share our full experience from wandering among the ancient Giant Sequoias in Mariposa Grove to standing at Tunnel View, taking in the panoramic sweep of El Capitan, Half Dome, and Bridalveil Fall. We talk about the beauty of Yosemite's dramatic cliffs, lush meadows, and powerful waterfalls, and what it feels like to hike through a place shaped by glaciers and time.We dive into what it actually takes to plan a Yosemite trip: navigating unpredictable weather, understanding trail conditions, and choosing the right gear when temperatures swing without notice. From the towering drop of Yosemite Falls — the tallest waterfall in the continental U.S. — to quiet moments on forested trails, we share the parts of Yosemite that surprised us, challenged us, and stayed with us long after we left the park.And, naturally, our adventure includes a joyful detour into California's fast-food scene — proof that even the most nature-heavy trips can be paired with chaotic, delicious road snacks. If you're planning a Yosemite itinerary, craving national park inspo, or simply want to immerse yourself in stories from the outdoors, this episode blends travel reflection, practical insight, and a whole lot of love for America's national parks.

Semarnat reconoce labor de núcleos agrarios en protección de la monarca  Primera tormenta invernal se aleja de México  La capilla más austral del mundo está en la Antártida  Más información en nuestro podcast

TIC lideran salarios, pero faltan especialistas: IMCO El Gobierno cuenta con el respaldo mayoritario del pueblo: SheinbaumInundaciones y deslizamientos golpean a VietnamMás información en nuestro podcast

Escuche esta y más noticias de LA PATRIA Radio de lunes a viernes por los 1540 AM de Radio Cóndor en Manizales y en www.lapatria.com, encuentre videos de las transmisiones en nuestro Facebook Live: www.facebook.com/lapatria.manizales/videos

Send us a textThis month we're talking all about spectating MTB races — the hype, the hill climbs, the cowbells, and why cheering from the sidelines is its own kind of adrenaline rush. Whether you've never been to a race or you're already a tape-side superfan, this episode breaks down what makes race weekends so much fun.We're also joined by Jen and Nadine, who share their favorite spectating moments and why upgrading to VIP access takes the whole experience to a new level.

Michael Dalle Molle serves as the Chief Operating Officer for Mariposa Technology, where he oversees daily business operations, communications, and brand management. He is an entrepreneur, teacher, business advisor, and environmentalist with almost a decade of professional experience as a sustainability advocate in the design and construction industry. Before entering the cannabis industry, Michael taught at the Tulane University School of Architecture and ran his design+build studio in New Orleans.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Agricultores bloquean carreteras en GuanajuatoConsejo Agropecuario pide soluciones sin afectaciones a la economía  Boric lanza dura crítica a Trump por negar cambio climáticoMás información en nuestro Podcast

Art in thumbnail by: Marcelo Costa There is a new threat looming over the Horizon. Marshall learns more about Mariposa. Radiant Black is a Massive-verse series. Radiant Black is a Massive-verse series. The Radiant Black Podcast Instagram: https://www.instagram.com/radiantblackpodcast/?hl=en The Radiant Black Podcast Patreon: https://www.patreon.com/radiantblackpodcast The Radiant Black Podcast Twitter: https://twitter.com/RadiantBlackPod Radiant Black Discord Link: https://discord.gg/n7y7ZFPUv9

Pues como dice el titulo, pocas cosas y poco relevantes, pero mola contarlas y escucharlas

Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC). We explored the latest treatment options, including: •⁠  ⁠Osimertinib •⁠  ⁠Amivantamab plus Lazertinib (based on the MARIPOSA trial) •⁠  ⁠Osimertinib plus chemotherapy (from the FLAURA2 trial) Listen in as we analyze real-life patient cases, focusing on a 58-year-old gentleman with CNS involvement and a 66-year-old woman experiencing disease progression after initial treatment. Dr. Singhi shared valuable insights on the importance of supportive care, the impact of treatment combinations, and the significance of repeat tissue profiling. Key topics covered: •⁠  ⁠The latest data from the MARIPOSA and FLAURA2 trials •⁠  ⁠Strategies for managing side effects and improving patient quality of life •⁠  ⁠The role of multidisciplinary teams in treatment planning •⁠  ⁠The importance of understanding resistance patterns in treatment decisions Whether you're a healthcare professional or simply interested in oncology, this episode is packed with essential information and expert perspectives.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from The Oncology Brothers! #EGFRNSCLC #Mariposa #Amivantamab #Osimertinib #FLAURA2 #OncologyBrothers #LungCancer

Mariposa, 5min,. USA Directed by Brook Vitovsky Mariposa's world begins to unravel around her when she finds a mysterious butterfly. Conversation with director: Brook Vitovsky. producer: Cambria Cheney. composer: Chase Miller. artist/writer: EmmaLeigh Fleck. artist: Kiera Vermeal Get to know the filmmaker: What motivated you to make this film? Growing up, I, Brook Vitovsky, watched my great-grandmother struggle with dementia. From the time I was a toddler until I was thirteen, I saw how the disease slowly affected her mind and spirit. Witnessing that experience firsthand made me realize how deeply dementia impacts not only those who live with it but also their families. My motivation for making this film comes from a desire to honor that experience — to reach people's hearts and create a sense of shared understanding and connection. From the idea to the finished product, how long did it take for you to make this film? My team and I worked on this film for over a year. How would you describe your film in two words!? Heartfelt and bittersweet What was the biggest obstacle you faced in completing this film? The biggest challenge we faced was definitely the layout. Matching the perspective from the storyboards to the 3D model in Maya proved difficult, especially when it came to controlling the camera. Subscribe to the podcast: https://twitter.com/wildsoundpod https://www.instagram.com/wildsoundpod/ https://www.facebook.com/wildsoundpod

México enfrenta una crisis de obesidad, diabetes e hipertensión: Sheinbaum SCJN invalida cobros desproporcionados en Hidalgo, Oaxaca y Chihuahua¿Por qué sentimos mariposas en el estómago?Más información en nuestro podcast

Dean Richards, Dave Schwan, Jack Heinrich and “Elton Jim” Turano start the show talking about their shared history in radio and the VHS workout craze of the ’80s. For today’s Far Flung Forecast, Dave takes us out to Mariposa, California. Dr. Santina Wheat, Program Director, McGaw Northwestern Family Medicine Residency Northwestern Medicine, Delnor Hospital, joins […]

In this special episode of the Sensitive and Neurodivergent Podcast, guest hosts Carol Ressler and Carolina Mariposa explore how parents and caregivers can create safe, supportive spaces for sensitive and neurodivergent children during life transitions—like moving to a new home, starting school, or welcoming a sibling. They share real-life examples of cozy nooks, sensory-friendly play areas, and calming rituals that help children regulate their emotions and feel secure. From crash pads and weighted blankets to twinkle lights, flower essences, and joyful pops of color, this heartfelt conversation offers practical, creative ideas to nurture sensitive kids. Whether you're a parent, caregiver, or professional, you'll find inspiration for making home a sanctuary that meets the unique needs of sensitive children—and yourself.Links mentioned in this episode: The Adventures of Niko, the Highly Sensitive DogTed Talk: Where Joy Hides and How to Find It Carolina Mariposa's websiteCarolina's emailFor more episodes and resources from Julie Bjelland, visit JulieBjelland.com

Parents outraged over comment Mariposa teacher allegedly made about Charlie Kirk's death Please Subscribe + Rate & Review Philip Teresi on KMJ wherever you listen! --- KMJ’s Philip Teresi is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi, Weekdays 2-6 PM Pacific News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Parents outraged over comment Mariposa teacher allegedly made about Charlie Kirk's death Please Subscribe + Rate & Review Philip Teresi on KMJ wherever you listen! --- KMJ’s Philip Teresi is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi, Weekdays 2-6 PM Pacific News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease. 4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.

Irene Calderón ha presentado a Javier García, un conductor de Metro de Madrid que en sus ratos libres es ultraciclista, es decir, hace etapas de 300-400 kilómetros sin apoyo y autosuficiente. Desde 2021 pedalea para dar visibilidad a una enfermedad rara, la Piel de Mariposa. En redes sociales se hace llamar Xinolugo y llega este fin de semana a Madrid después de 23 días y 6.000 kilómetros con su proyecto Igare. 

Irene Calderón ha presentado a Javier García, un conductor de Metro de Madrid que en sus ratos libres es ultraciclista, es decir, hace etapas de 300-400 kilómetros sin apoyo y autosuficiente. Desde 2021 pedalea para dar visibilidad a una enfermedad rara, la Piel de Mariposa. En redes sociales se hace llamar Xinolugo y llega este fin de semana a Madrid después de 23 días y 6.000 kilómetros con su proyecto Igare. 

Mead makes its merry way into the episode, though we don't drink any. Hash tag sad face. A terrific flight though and wonderful can art. Head to Mariposa to Twisted Cedar and tell Steve what stouts he should be carrying!

Jorge Laborda nos acerca a un antiviral universal. Investigadores de Nueva York han creado moléculas sintéticas que se unen a los azúcares que recubren muchos virus y bloquean su entrada en la célula. Han funcionado contra siete virus distintos. En ratones, el 90 % sobrevivió tras la infección. Y lo mejor: los virus no pueden cambiar fácilmente esos azúcares, porque dependen de la célula huésped. Eso significa menos riesgo de resistencias. A continuación, Angel Rodríguez Lozano comenta un descubrimiento que llega del espacio. El telescopio James Webb ha observado la Nebulosa de la Mariposa, los restos de una estrella moribunda. Ha encontrado cristales de silicato formados lentamente y burbujas de gas expulsadas en violentas erupciones. Y algo aún más sorprendente: la primera evidencia de que los PAHs, moléculas de carbono esenciales para la vida, pueden formarse en plena nebulosa planetaria.

Jorge Laborda nos acerca a un antiviral universal. Investigadores de Nueva York han creado moléculas sintéticas que se unen a los azúcares que recubren muchos virus y bloquean su entrada en la célula. Han funcionado contra siete virus distintos. En ratones, el 90 % sobrevivió tras la infección. Y lo mejor: los virus no pueden cambiar fácilmente esos azúcares, porque dependen de la célula huésped. Eso significa menos riesgo de resistencias. A continuación, Angel Rodríguez Lozano comenta un descubrimiento que llega del espacio. El telescopio James Webb ha observado la Nebulosa de la Mariposa, los restos de una estrella moribunda. Ha encontrado cristales de silicato formados lentamente y burbujas de gas expulsadas en violentas erupciones. Y algo aún más sorprendente: la primera evidencia de que los PAHs, moléculas de carbono esenciales para la vida, pueden formarse en plena nebulosa planetaria.

Episode 1779 - brought to you by our incredible sponsors: Poncho - If you've been looking for the perfect shirt—something breathable, fits great, feels even better, and stands out in a good way—give Poncho a try.  Go to www.ponchooutdoors.com/hardfactor for $10 off your first order. Lucy - Let's level up your nicotine routine with Lucy.  Go to ⁠⁠Lucy.co/HARDFACTOR⁠⁠ and use promo code (HARDFACTOR) to get 20% off your first order. Lucy has a 30-day refund policy if you change your mind. Brooklyn Bedding -  Go to brooklynbedding.com and use code HARDFACTOR at checkout to get 30% off sitewide. This offer is not available anywhere else.   DaftKings - Download the DraftKings Casino app, sign up with code HARDFACTOR, and spin your favorite slots! The Crown is Yours - Gambling problem? Call one eight hundred GAMBLER 00:00:00 Timestamps 00:05:10 Serial butt sniffer arrested AGAIN!!  00:13:45 New Chiefs sideline correspondent is HOTT  00:22:40 Mariposa, CA, DA was buying Meth for 8 years and God knows what else 00:27:55 The Florida Board of Education will no longer hand out certificates to students with disabilities who could not earn the diploma, but tried really hard 00:29:50 President Trump wants to send the National Guard to Chicago 00:34:25 French marine park is jerking off its male Orca so it doesn't try to have sex with his own mother Thank you for listening!! Go to ⁠patreon.com/hardfactor⁠ to join our community. We love you, and most importantly HAGFD! Learn more about your ad choices. Visit megaphone.fm/adchoices

We follow the monarch butterfly on her journey.

Eddie Jones shares his architectural journey, from his education to founding Jones Studio. He reflects on his early career and significant projects, including the St. Louis (now Arizona) Cardinals training facility and the Scottsdale Museum of Contemporary Art exhibit. Eddie discusses the Mariposa land port of entry project and the studio's growth. He provides insights into succession planning and transitioning roles within the studio, emphasizing his evolution from architect to business leader.

En El Faro 'caos' David Botello ha organizado su sección más caótica. Todo empieza con una mariposa que bate sus alas... Y acaba con un rap hecho por el propio colaborador.

What happens when a group of kids on horseback stumble into a hidden meadow deep in the Sierra Nevadas — and realize they're not alone? In this gripping episode, we speak with Loadmaster, a veteran who shares a chilling childhood encounter from the backwoods just south of Yosemite National Park. Snapped pine trees. A smell worse than death. Horses panicking beneath them. And the realization — confirmed by Native Me-Wuk elders — that they had crossed into forbidden territory.Loadmaster recounts a terrifying moment etched into his memory for over 50 years, where the forest itself seemed to push them back. You'll hear how journals from the 1800s spoke of “hairy men” destroying mining equipment, and why locals still avoid those uncharted hills to this day. From stories of juvenile Sasquatch sightings to tales of entire families migrating through lightning storms, this episode uncovers a side of Yosemite few have ever heard — and most are wise enough to leave alone.But the mystery doesn't stop there.You'll also hear from a woman who saw a Bigfoot from the window of a moving train in Canada at just 13 years old… a truck driver whose early-morning route through Illinois brought him face to face with something massive by the road… a camper in Northern California who heard heavy footsteps circling his tent all night… and a quiet stretch of river in South Carolina where something huge came walking out of the water.These aren't just backwoods legends. They're warnings.And some places… you only find once.

Buenos días, soy Yoani Sánchez y en el "cafecito informativo" de este lunes 28 de julio de 2025 tocaré estos temas: - Un reporte oficial con precios "maquillados" desata la indignación - Altos consumidores de combustible, los todoterrenos rusos ensamblados en Cuba - La violencia machista se cobra otra víctima - Exposición ‘La estrategia del Bambú' Gracias por compartir este "cafecito informativo" y te espero para el programa de mañana. Puedes conocer más detalles de estas noticias en el diario https://www.14ymedio.com Los enlaces de hoy, para abrirlos desde la Isla se debe usar un proxy o un VPN para evadir la censura: El secreto bien guardado del éxito de la empresa estatal La Cuba en Ciego de Ávila https://www.14ymedio.com/economia/secreto-guardado-exito-empresa-estatal_1_1116348.html Maltratada durante años, Kenia muere al ser arrojada por su pareja desde la azotea de su vivienda https://www.14ymedio.com/cuba/maltratada-durante-anos-kenia-muere_1_1116373.html Altos consumidores de combustible, los todoterrenos rusos que rodarán por las calles cubanas https://www.14ymedio.com/cuba/altos-consumidores-combustible-todoterrenos-rusos_1_1116335.html Regresa la Mariposa: promesas, ruinas y nostalgia en el parque Lenin de La Habana https://www.14ymedio.com/cuba/regresa-mariposa-promesas-ruinas-nostalgia_1_1116322.html "Sin 'Mazzantini' no hay país" https://www.14ymedio.com/cultura/mazzantini-no-hay-pais_1_1116315.html Rusia propone crear un ‘Silicon Valley' en la Isla de los apagones https://www.14ymedio.com/cuba/rusia-propone-crear-silicon-valley_1_1116310.html El rapero Nando OBDC se mantiene en huelga de hambre y está incomunicado https://www.14ymedio.com/cuba/rapero-nando-obdc-mantiene-huelga_1_1116356.html Una madre desesperada recorre La Habana en busca de su hija desaparecida hace cuatro meses https://www.14ymedio.com/cuba/madre-desesperada-recorre-habana-busca_1_1116346.html Una abuela cubana recibe una orden de deportación tras 30 años en EE UU https://www.14ymedio.com/migracion/abuela-cubana-recibe-orden-deportacion_1_1116353.html ​​La estrategia del Bambú, exposición de Felipe Dulzaides https://www.14ymedio.com/cartelera/estrategia-bambu-exposicion-felipe-dulzaides_1_1116214.html

Aseguran bodega con combustible robado en Tres Marías, MorelosMás de 200 jardines y huertos polinizadores para la mariposa monarca Netanyahu condena decisión de Macron de reconocer al Estado palestinoMás información en nuestro Podcast

Assemblyman David Tangipa joins Darcy and Darcy for a great conversation that covers a wide range of California issues and topics! For those that don't know him yet, David is the youngest person serving in the California legislature. He was elected to the California State Assembly in 2024 and represents District 8, which includes Calaveras, Fresno, Inyo, Madera, Mariposa, Mono, and Tuolumne counties.  Darcy & Darcy discuss with David his perspective on the business of California's legislature, his first six months in office, some great ideas he has about putting existing infrastructure to work doing double duty, the impact the Groundwater Sustainability Act has had on his constituents, and most importantly, lessons learned.One thing is clear: David is an upcoming California policy leader. The ECPAC is looking forward to hosting a fundraiser for David on July 31st at noon at M & M's Italian Restaurant in Los Banos. If you would like to support David or join us for lunch, please contact Terra at (559) 281-9088 or email her at tbrusseau@centralvalleygroup.com. All are welcome to attend.To learn more about Assemblyman Tangipa and District 8 visit www.ad08.asmrc.org/.Send us a textWe Grow California Podcast is paid for by the Exchange Contractors Federal PAC and Exchange Contractors State PAC and is not authorized by any candidate or candidate committee.

 Em agosto de 2021, a família Gerrish, composta por John, Ellen, Miju e Oski foram fazer uma trilha na Floresta Nacional de Sierra, no Condado de Mariposa. Depois que eles não voltaram para casa, seus amigos acionaram as autoridades. O que aconteceu com a família Gerrish? #510

Episode Description:In this uplifting episode, “The Butterfly Who Wanted to Fly”, we meet Lila, a colorful little butterfly with big wings—and an even bigger fear of flying. With the help of her friend Nico the hummingbird, Lila learns that courage isn't about being unafraid, but about trusting yourself enough to try. This gentle story is all about bravery, growth, and taking that first leap.Want the full transcript, vocabulary list, and printable story bundle? Join our monthly membership to support the podcast on Patreon at patreon.com/spanishstoriesforkids.And if you have a story you'd like us to read, email us at spanishstoriespodcast@gmail.com—we'd love to hear it!En este episodio inspirador, “La Mariposa Que Quería Volar”, conocemos a Lila, una pequeña mariposa llena de color, con alas grandes… y un miedo aún más grande a volar. Con la ayuda de su amigo Nico, un colibrí, Lila aprende que el valor no significa no tener miedo, sino confiar lo suficiente en uno mismo para intentarlo. Esta historia suave nos habla de la valentía, el crecimiento y ese primer gran salto.¿Quieres la transcripción completa, la lista de vocabulario y un paquete imprimible del cuento? Únete a nuestra membresía mensual para apoyar el podcast en Patreon: patreon.com/spanishstoriesforkids.¿Tienes una historia que te gustaría que leamos? Escríbenos a spanishstoriespodcast@gmail.com—¡nos encantaría recibirla!

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

El Viene y Va podcast regresa después de 6 meses, más honesto, más divertido, más fresco. En el episodio de hoy, Dani cuenta sobre un encuentro que tuvo con alguien de su pasado, y como este momento la llevó a aprender más sobre el efecto mariposa y como se aplica al día a día.www.danigschulz.com | IG: @danigschulz | TikTok: @danigschulz

This is part two of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is part one of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"What kind of saber are you rockin?"Mariposa and Archie bite off more than they can chew during a nighttime canyon crawl.Episode Artwork by @shaunmakesAudio Production by Astronomic AudioMusic by Duke Albert, John Julius, Mike Hammock, and ShubertFeaturing:Shaun as The Game MarshalCristina as Mariposa Dela Cruz RosalesDan as Archie ElseworthJanette as Killdread SprainsShubert as Billy Bigtoes—Need More Bob in Your Life? Check out our other (SFW!) podcast, Tales of BobApple PodcastsSpotify—Support the Show:PatreonMerch StoreContact Us:DiscordTheHouseOfBob.orgTwitterInstagramFacebookEmail—Thank you so much to our current Patreon supporters! This podcast would not be possible without you.MichaelCarlos GShaka JamalEthan EdwardsDan Klip-KlopElliThe Pink PastorGarbanzoD ChanAnette E JordanThomas KuhlmannConnor McCollochPadraig HegartyBrandon KnoxTeam EAMONNPavel LishinChristine BrailleTom InnsElias AndersonMark BoykinJessica ColvinScooter EmersonJosh JordanKeith HaddadTom WesleyJessica

Aprovecha la promoción exclusiva de NordVPN y Leyendas Legendarias y obtén 4 meses gratis: https://nordvpn.com/legendarias Notas Macabrosas - Muere un joven de 14 años por inyectarse 'jugo de mariposa' - Una prueba de ADN confirma que las lágrimas de la Virgen de Trevignano eran de una vidente - Presunto artefacto explosivo resulta ser un envase de perfume - Escapando de la “granja de huevos humanos”: tres mujeres escapan de una impactante red de tráfico de personas - Mujer se divorcia porque su esposo abucheó a Taylor Swift en Super Bowl - Atleta de 17 años murió mientras levantaba una barra con 270 kg  - 157 delfines fueron hallados varados en una playa de Tasmania  - California avanza hacia el reconocimiento oficial de Bigfoot  - Rescatan a hombre encerrado en baño de Elektra  - Hombre es detenido en aeropuerto con 19 cápsulas de cocaína en una peluca  - Un hombre mata a su esposa después de que un medidor paranormal le provocara temores de que ella se lo comería Redditeando - Lolo nos trae un hilo de reddit con respuestas a la pregunta: ¿Cuál es tu “rasgo de asesino en serie” que (hipotéticamente) haría que todos dijeran: “Deberíamos haberlo sabido”? También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices